Nuvectis Pharma, Inc. (NVCT)
NASDAQ: NVCT · Real-Time Price · USD
23.56
+0.21 (0.90%)
Aug 21, 2026, 4:00 PM EDT - Market closed
Nuvectis Pharma Employees
Nuvectis Pharma had 16 employees as of June 30, 2026. The number of employees increased by 3 or 23.08% compared to the same quarter last year.
Employees
16
Change
3
Growth
23.08%
Revenue / Employee
n/a
Profits / Employee
-$1,892,188
Market Cap
767.62M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 16 | 3 | 23.08% |
| Mar 31, 2026 | 12 | -1 | -7.69% |
| Dec 31, 2025 | 13 | 0 | - |
| Sep 30, 2025 | 13 | 0 | - |
| Jun 30, 2025 | 13 | 0 | - |
| Mar 31, 2025 | 13 | 0 | - |
| Dec 31, 2024 | 13 | 0 | - |
| Sep 30, 2024 | 13 | 0 | - |
| Jun 30, 2024 | 13 | - | - |
| Dec 31, 2023 | 13 | 2 | 18.18% |
| Dec 31, 2022 | 11 | 3 | 37.50% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Gyre Therapeutics | 625 |
| Phathom Pharmaceuticals | 371 |
| REGENXBIO | 371 |
| Allogene Therapeutics | 152 |
| Neurogene | 131 |
| BridgeBio Oncology Therapeutics | 106 |
| Cybin | 100 |
| CytomX Therapeutics | 69 |
NVCT News
- 11 hours ago - Nuvectis Pharma files $200M mixed securities shelf - TheFly
- 20 hours ago - Nuvectis Pharma Registration statement: Registration filing - Filings
- 11 days ago - Nuvectis Pharma Slides: Corporate presentation - Filings
- 16 days ago - Nuvectis Pharma price target raised to $34 from $22 at Lucid Capital - TheFly
- 17 days ago - Nuvectis Pharma Earnings release: Q2 2026 - Filings
- 17 days ago - Nuvectis Pharma Quarterly report: Q2 2026 - Filings
- 17 days ago - Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights - GlobeNewsWire
- 4 weeks ago - Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors - GlobeNewsWire